Quantum Circuits, Inc. (QCI) was founded in 2015 with the goal of developing, manufacturing and selling the first practical and useful quantum computers based on superconducting devices. QCI was founded by pioneers in quantum devices and information processing from the Department of Applied Physics at Yale University. Their group has produced many scientific firsts, including the development of a “quantum bus” for entangling qubits with wires and the first implementation of a quantum algorithms and error-correction with a solid-state device.
Status: Private
Dispatch
Dispatch is a data orchestration platform powering cross-application workflows for financial advisors, enabling them to seamlessly sync client data across the advisor tech stack and to free them from continually building and maintaining integrations.
OnCusp Therapeutics
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
Shinobi Therapeutics
Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system.
T-Therapeutics
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge. The company was created to harness the power of T cell biology, evolved over millions of years, to create safe and effective treatments for many cancers and autoimmune diseases.
AlphaGen Therapeutics
AlphaGen Therapeutics is a radiopharmaceutical company focused on the discovery, development and commercialization of innovative targeted radioligand therapies (RLTs). Leveraging its cutting-edge technology platform, the company aims to develop targeted RLTs for patients in China and around the world.
Tenpoint Therapeutics
Tenpoint Therapeutics™ is pioneering a new treatment for presbyopia, BRIMOCHOL™ PF, with a PDUFA date from US FDA of January 28, 2026. The company also has a R&D pipeline of novel therapies for other unmet needs in ophthalmology.
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO’s approach uses the optimal alpha-emitting isotope (Pb212) with tumor-specific targets to create unique radioligand therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
Albert Invent
Albert Invent is an end-to-end R&D platform for chemists and materials scientists, combining ELN, LIMS, inventory, and regulatory tools in one system. Powered by its AI engine, Breakthrough™, trained on over 15 million molecular structures, Albert enables predictive formulation, inverse design, and faster innovation cycles for the worlds largest chemical companies.
Cadence Neuroscience
Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. The company’s core technology was developed at Mayo Clinic and is under clinical evaluation. Founded in 2017 and headquartered in Redmond, Washington, Cadence is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies.